Hua Medicine (HKSE:02552) Debt-to-Revenue : 13.36 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Hua Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$45.36 Mil. Hua Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$138.13 Mil. Hua Medicine's annualized Revenue for the quarter that ended in Dec. 2023 was HK$13.74 Mil. Hua Medicine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 13.36.

Hua Medicine Debt-to-Revenue Historical Data

The historical data trend for Hua Medicine's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Debt-to-Revenue Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

5.55

2.19

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial										N/A	N/A	2.77	1.54	13.36

Competitive Comparison of Hua Medicine's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hua Medicine's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hua Medicine's Debt-to-Revenue falls into.

Hua Medicine Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Hua Medicine's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(45.36	+	138.126)	/	83.794
	=	2.19

Hua Medicine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(45.36	+	138.126)	/	13.736
	=	13.36

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Hua Medicine Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine (HKSE:02552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

N/A

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.

Hua Medicine (HKSE:02552) Headlines

No Headlines